Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

162
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
162
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

197
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
197
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

111
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
111
Survival Curves01:18

Survival Curves

116
Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
116
Censoring Survival Data01:09

Censoring Survival Data

72
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
72
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

525
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
525

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development.

Nature reviews. Drug discovery·2026
Same author

Individualised duration of antibiotic treatment in culture-negative early-onset sepsis in late-preterm and term-born neonates in Denmark (DURATION): a multicentre, open-label, randomised, controlled, non-inferiority trial.

The Lancet. Child & adolescent health·2026
Same author

Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Early discontinuation of empirical antibiotics versus extended treatment in children with cancer and high-risk febrile neutropenia in Denmark: an open-label, randomised controlled trial.

The Lancet. Child & adolescent health·2026
Same author

The Ki-67 proliferation index and recurrence risk of intracranial meningioma: a multicenter, retrospective cohort study of 5,050 patients.

Acta neurochirurgica·2026
Same author

Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.

Genome medicine·2026

Related Experiment Video

Updated: Jun 16, 2025

Author Spotlight: Investigating the Role of Repetitive DNA Misregulation in Cancer Initiation and Immunotherapy Resistance
04:58

Author Spotlight: Investigating the Role of Repetitive DNA Misregulation in Cancer Initiation and Immunotherapy Resistance

Published on: December 13, 2024

2.2K

Design and Analysis of Group Sequential Trials for Repeated Measurements When Pipeline Data Occurs: A Tutorial.

Corine Baayen1,2, Paul Blanche3, Christopher Jennison4

  • 1Biometric Division, H. Lundbeck A/S, Valby, Denmark.

Statistics in Medicine
|June 13, 2025
PubMed
Summary

Group sequential trials (GST) with delayed endpoints can be statistically optimized. This study provides methods to effectively analyze data from pipeline patients, increasing statistical power for clinical trial decision-making.

Keywords:
delayed outcomeserror spending functionsgroup sequential trialspipeline patientsrepeated measurements

More Related Videos

Databases to Efficiently Manage Medium Sized, Low Velocity, Multidimensional Data in Tissue Engineering
09:43

Databases to Efficiently Manage Medium Sized, Low Velocity, Multidimensional Data in Tissue Engineering

Published on: November 22, 2019

6.2K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K

Related Experiment Videos

Last Updated: Jun 16, 2025

Author Spotlight: Investigating the Role of Repetitive DNA Misregulation in Cancer Initiation and Immunotherapy Resistance
04:58

Author Spotlight: Investigating the Role of Repetitive DNA Misregulation in Cancer Initiation and Immunotherapy Resistance

Published on: December 13, 2024

2.2K
Databases to Efficiently Manage Medium Sized, Low Velocity, Multidimensional Data in Tissue Engineering
09:43

Databases to Efficiently Manage Medium Sized, Low Velocity, Multidimensional Data in Tissue Engineering

Published on: November 22, 2019

6.2K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Statistical Inference

Background:

  • Group sequential trials (GST) enable early stopping for efficacy or futility.
  • Established GST methods are less developed for delayed or repeated outcome measurements.
  • Pipeline subjects with early data present analytical challenges in interim analyses.

Purpose of the Study:

  • To provide guidance on planning and analyzing GST with repeated measurements and delayed endpoints.
  • To enhance statistical power by incorporating early outcome data from pipeline subjects.
  • To offer practical tools, including an R package, for implementing these advanced GST methods.

Main Methods:

  • Discussing and expanding upon existing statistical methods for GST with delayed endpoints.
  • Developing computational details for valid p-values and confidence intervals.
  • Incorporating nonbinding stopping rules for futility in interim analyses.

Main Results:

  • Methods are presented to formally incorporate all available data, including from pipeline subjects.
  • The approach increases statistical power by utilizing early measurements.
  • Valid statistical inference (p-values, confidence intervals) is achievable with the proposed methods.

Conclusions:

  • This paper offers a comprehensive guide for designing and analyzing GST with delayed endpoints and repeated measures.
  • The proposed methods effectively leverage data from pipeline patients to improve trial efficiency and power.
  • Accessible R code and a package are provided to facilitate the application of these advanced statistical techniques.